

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Yukio NIHEI, et al.

SERIAL NO: New Application

GAU:

FILED: Herewith

EXAMINER:

FOR: ANTI-TUMOR AGENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter
Registration No. 32,884

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Vincent K. Shier, Ph.D.
Registration No. 50,552

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 245553US0CONT		SERIAL NO. New Application	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT					
		Yukio NIHEI, et al.					
		FILING DATE		GROUP		Herewith	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	WO 98/32440 A1	07/30/98	WIPO	YES		NO
	AP	WO 97/05870 A2	02/20/97	WIPO			
	AQ	EP 1 068 870 A1	01/17/01	Europe			
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
AW	Raymond B. Weiss et al., "HYPERSENSITIVITY REACTIONS FROM TAXOL", Journal of Clinical Oncology, Vol. 8, No. 7, pp. 1263-1268, July 1990.						
AX	Eckhardt Sandor et al., "THE EFFECT OF DOCETAXEL ON MALIGNANT TUMORS", Orvosi Hetilap, Vol. 139, No. 15, pp. 867-872, 1998.						
AY	George P. Browman, "MODIFIED ADRIAMYCIN-VINCRISTINE-DEXAMETHASONE (m-VAD) IN PRIMARY REFRACTORY AND RELAPSED PLASMA CELL MYELOMA: AN NCI (CANADA) PILOT STUDY", British Journal of Haematology, Vol. 82, pp. 555-559, 1992.						
AZ					<input type="checkbox"/> Additional References sheet(s) attached		
Examiner					Date Considered		

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.